Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Related Citations for PubMed (Select 22430269)

1.

Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care.

Pirl WF, Greer JA, Traeger L, Jackson V, Lennes IT, Gallagher ER, Perez-Cruz P, Heist RS, Temel JS.

J Clin Oncol. 2012 Apr 20;30(12):1310-5. doi: 10.1200/JCO.2011.38.3166. Epub 2012 Mar 19.

2.

Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer.

Pirl WF, Traeger L, Greer JA, Jackson V, Lennes IT, Gallagher E, Sequist L, Temel JS.

Palliat Support Care. 2013 Jun;11(3):223-9. doi: 10.1017/S1478951512001071. Epub 2013 Feb 11.

PMID:
23399428
3.

Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.

Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S.

J Clin Oncol. 2004 Mar 1;22(5):801-10.

5.

Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.

Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Heist RS, Gallagher ER, Temel JS.

J Clin Oncol. 2012 Feb 1;30(4):394-400. doi: 10.1200/JCO.2011.35.7996. Epub 2011 Dec 27.

6.

Early palliative care for patients with metastatic non-small-cell lung cancer.

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ.

N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678.

7.
8.
9.

Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial.

Falk SJ, Girling DJ, White RJ, Hopwood P, Harvey A, Qian W, Stephens RJ; Medical Research Council Lung Cancer Working Party.

BMJ. 2002 Aug 31;325(7362):465.

10.

Relationship between deficits in overall quality of life and non-small-cell lung cancer survival.

Sloan JA, Zhao X, Novotny PJ, Wampfler J, Garces Y, Clark MM, Yang P.

J Clin Oncol. 2012 May 1;30(13):1498-504. doi: 10.1200/JCO.2010.33.4631. Epub 2012 Mar 26.

11.
12.

Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer.

Qi Y, Schild SE, Mandrekar SJ, Tan AD, Krook JE, Rowland KM, Garces YI, Soori GS, Adjei AA, Sloan JA.

J Thorac Oncol. 2009 Sep;4(9):1075-82. doi: 10.1097/JTO.0b013e3181ae27f5.

13.

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.

Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J.

Br J Cancer. 2000 Aug;83(4):447-53.

14.

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M.

J Clin Oncol. 2005 Sep 20;23(27):6674-81.

15.

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH.

J Clin Epidemiol. 2002 Mar;55(3):285-95.

PMID:
11864800
16.

Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM.

J Clin Oncol. 2011 Nov 10;29(32):4320-6. doi: 10.1200/JCO.2011.35.5214. Epub 2011 Oct 11.

17.

Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer.

Walker J, Hansen CH, Martin P, Symeonides S, Gourley C, Wall L, Weller D, Murray G, Sharpe M; SMaRT (Symptom Management Research Trials) Oncology-3 Team.

Lancet Oncol. 2014 Sep;15(10):1168-76. doi: 10.1016/S1470-2045(14)70343-2. Epub 2014 Aug 27.

PMID:
25175097
18.
19.

Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer.

Nwogu CE, Groman A, Fahey D, Yendamuri S, Dexter E, Demmy TL, Miller A, Reid M.

Ann Thorac Surg. 2012 May;93(5):1614-9; discussion 1619-20. doi: 10.1016/j.athoracsur.2012.01.065. Epub 2012 Mar 20.

PMID:
22440365
20.

Significant progress in palliative treatment of non-small cell lung cancer in the past decade.

Waechter F, Passweg J, Tamm M, Brutsche M, Herrmann R, Pless M.

Chest. 2005 Mar;127(3):738-47.

PMID:
15764752
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk